Lignans isolated from Piper truncatum act as new potent antitrypanosomal compounds
Marina Monroe Gonçalves, Carlos Henrique Totini, Erica V de Castro, Vanessa Albuquerque, Guilherme Medeiros Antar, Andre Gustavo Tempone, João Henrique G. Lago- Molecular Biology
- Molecular Medicine
- General Chemistry
- Biochemistry
- General Medicine
- Bioengineering
The hexane extract from twigs of Piper truncatum Vell (Piperaceae) displayed activity against Trypanosoma cruzi and was subjected to chromatographic steps to afford six dibenzylbutyrolactolic lignans, being four knowns: cubebin (1), (‐)‐9α‐O‐methylcubebin (2), (+)‐9β‐O‐methylcubebinin (3) and 3,4‐dimethoxy‐3,4‐demethylenedioxycubebin (4) as well as two new, named truncatin A (5) and B (6). Initially, in vitro activity against trypomastigotes was evaluated and compounds 1, 4 and 6 exhibited EC50 values of 41.6, 21.0 and 39.6 μM, respectively. However, when tested against amastigotes, the relevant clinical form in the chronic phase of Chagas disease, compounds 1 – 6 displayed activities with EC50 values ranging from 1.6 to 13.7 μM. In addition, the mammalian cytotoxicity of compounds 1 – 6 was evaluated against murine fibroblasts (NCTC). Compounds 2, 3 and 4 exhibited reduced toxicity against NCTC cells (CC50 > 200 μM), resulting in SI values of > 21.9, > 14.5 and > 121.9, respectively. Compound 4 showed the highest potency with an SI value twice superior to that determined by the standard drug benznidazole (SI > 54.6) against the intracellular amastigotes. These data suggest that lignan 4 can be considered a possible scaffold for designing a new drug candidate for Chagas disease.